Chiropractors in Smethport, PA Accepting Medicare

3 Chiropractors found. Showing 1 - 3

Kio Chiropractic Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 301 W Main St, Smethport, PA 16749 Phone: 814-568-2083

Dr. Ryan Thomas Kio, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 301 W Main St, Smethport, PA 16749 Phone: 814-568-2083

Spryce York, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 301 W Main St, Smethport, PA 16749 Phone: 814-568-2083    Fax: 814-568-2075

News Archive

Calcium scoring test may predict risk of heart disease

Coronary calcium in heart arteries provides important clues about risk, even among younger and elderly patients and those without traditional risk factors, according to new studies.

Circuit awarded contract to pursue optogenetic therapies for peripheral nervous system indications

Circuit Therapeutics today announced that it has been awarded a 2.7 million dollar contract from the Defense Advanced Research Projects Agency to pursue optogenetic therapies for peripheral nervous system indications. The award, part of DARPA's Electrical Prescriptions (ElectRX) program, will enable Circuit to pursue research and development projects related to its treatment for neuropathic pain.

Clinical studies confirm safety, efficacy of opicapone in Parkinson's disease patients

BIAL is presenting 11 research posters at the 19th International Congress of Parkinson's Disease and Movement Disorders (June 14–15, San Diego, CA). These evaluate the safety and efficacy of opicapone (BIA 9-1067), a novel once-daily catechol-O-methyltransferase (COMT) inhibitor for use as adjunctive therapy in levodopa-treated Parkinson's disease patients with end of dose motor fluctuations.

Boron-based molecules can be used as new pharmacophores

Chemists and biologists have successfully demonstrated that specially synthesized boron compounds are readily accepted in biologically active enzymes, a move that, they say, is a proof of concept that could lead to new drug design strategies.

Sangamo presents immunological data from SB-728-T HIV clinical study at CROI 2016

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of immunological data from the Company's clinical trials of SB-728-T, a ZFP Therapeutic designed to provide functional control of HIV.

Read more Medical News

› Verified 2 days ago